From September 21st to 24th, the National Medical Products Administration held the unveiling ceremonies of the drug and medical device review and inspection sub-centers in Beijing, Wuhan, Hubei Province, and Chongqing respectively. Li Li, the Party Secretary and Director of the National Medical Products Administration, along with his team, attended the unveiling ceremonies and conducted research on the local pharmaceutical industry development and the establishment of the branch centers.

Li Li emphasized that the Beijing-Tianjin-Hebei Branch Center, the Central China Branch Center, and the Southwest Branch Center should, in accordance with the unified deployment of the National Medical Products Administration, adhere to high-level planning, high-standard construction, and high-quality development. They should steadily develop review and inspection capabilities that are in line with the characteristics of regional industries, and earnestly promote the construction of professional and specialized review and inspection teams. By providing efficient review and inspection services, they should help the regions build highlands of pharmaceutical innovation, inject vigorous impetus into the high-quality development of China's pharmaceutical industry, and continuously meet the people's new expectations for the quality and safety of drugs and medical devices as well as their innovative development.